

6 State of New Product Development (as of April 30, 2019)

i. Autoimmune diseases

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-1303 (Amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe Phase 2	In-house
	(Crohn's disease)	Japan Phase 2	
MT-7117	Dermatologicals, etc. (Erythropoietic protoporphyria)	Global Phase 2	In-house
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house
	(Seasonal Allergic Rhinitis)	Phase 1	

ii. Diabetes and kidney diseases

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
	(Diabetic nephropathy)	US Filed (Mar. 2019)	Licensed to Janssen Pharmaceuticals (US)
		Japan Phase 3	In-house
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Phase 3	
		Europe Phase 2	
MT-6548 (Vadadustat)	Hypoxia inducible factor prolyl hydroxylase inhibitor (Renal anemia)	Japan Phase 3	Licensed from Akebia (US)
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	In-house
		Japan Phase 2	
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2	

Asia: excluding Japan and China

iii. Central nervous system diseases

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Europe Filed (May 2018)	In-house
		China Filed (Apr. 2019)	
		Asia Filed	
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-210 (Risperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Phase 2/3	Licensed from Neurocrine Biosciences (US)
MT-8554	Nervous system, etc. (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
ND0612 (Levodopa/Carbidopa)	Continuous SC pump/patch pump (Parkinson's disease)	Global Phase 2	In-house
ND0701 (Apomorphine)	Continuous SC pump (Parkinson's disease)	Phase 1	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Phase 1	In-house
MT-6345	Nervous system	Phase 1	Co-developed with Ube Industries (Japan)

iv. Vaccines

Development code	Category (Indications)	Region Stage	Origin/licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	US, Europe Phase 3	Medicago product (Canada)
	(Prophylaxis of seasonal influenza/elderly)	US, Europe Phase 3	
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)

Asia: excluding Japan and China

v. Other diseases

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
TAU-284 Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Allergic rhinitis, Urticaria)	Asia Filed	Licensed from Ube Industries (Japan)
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism)	Japan Filed (Apr. 2019)	Licensed to Kyowa Hakko Kirin (Japan)
MT-4129	Cardiovascular system, etc.	Phase 1	In-house

Asia: excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of Apr 30, 2019	Origin / licensee
Azanin (Azathioprine)	Immunosuppressant (Autoimmune hepatitis)	Japan Filed (Aug. 2018)	Japan Approved (Feb. 2019)	Licensed from GlaxoSmithKline (UK)
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Switzerland Filed (Dec. 2017)	Switzerland Approved (Jan. 2019)	In-house
		None	China Filed (Apr. 2019)	
		None	Asia Filed	
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Japan, US, Europe, and others Phase 3 (Global clinical trial)	US Filed (Mar. 2019)	Licensed to Janssen Pharmaceuticals (US)
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism)	Japan Phase 3	Japan Filed (Apr. 2019)	Licensed to Kyowa Hakko Kirin (Japan)
MT-2990	Fully human anti-interleukin- 33 (IL-33) monoclonal antibody (Endometriosis)	Phase 1	Global Phase 2	In-house
Y-803	Bromodomain inhibitor (Cancer)	Europe,Canada Phase 2	Deleted (Termination of license agreement with Merck)	Licensed to Merck (US)

Asia: excluding Japan and China